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.2012.03.0Abstract Quinoline or 1-aza-naphthalene is a weak tertiary base. Quinoline ring has been found to
possess antimalarial, anti-bacterial, antifungal, anthelmintic, cardiotonic, anticonvulsant, anti-
inﬂammatory, and analgesic activity. Quinoline not only has a wide range of biological and phar-
macological activities but there are several established protocols for the synthesis of this ring. The
article aims at highlighting these very diversities of the ring.
ª 2012 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.N
11. Introduction
Quinoline [1] or 1-aza-napthalene or benzo[b]pyridine is nitro-
gen containing heterocyclic aromatic compound. It has a
molecular formula of C9H7N and its molecular weight is
129.16. The logP value is 2.04 and has an acidic pKb of 4.85
and a basic pKa of 9.5. Quinoline is a weak tertiary base. It
can form salt with acids and displays reactions similar to those
of pyridine and benzene. It shows both electrophilic and nucle-
ophilic substitution reactions. It is nontoxic to humans on oral
absorption and inhalation.91 11 26059681, +91
5; fax: +91 11 26059686.
(M.M. Alam).
Saud University.
g by Elsevier
. Production and hosting by Elsev
02Quinoline nucleus occurs in several natural compounds
(Cinchona Alkaloids) and pharmacologically active substances
displaying a broad range of biological activity. Quinoline has
been found to possess antimalarial, anti-bacterial, antifungal,
anthelmintic, cardiotonic, anticonvulsant, anti-inﬂammatory,
and analgesic activity. A few promising compounds [2–6] with
quinoline ring system are given in Fig. 1.2. Synthesis
A number of established protocols are there for the synthesis
of quinoline ring, which can be well modiﬁed to prepare a
number of differently substituted quino-lines.
2-Phenylquinoline-4-carboxylic acid [7] has been synthe-
sized by treatment of 2-oxopropionic acid with aniline and
benzaldehyde in the presence of rare earth metal catalysts
and reﬂuxing in water (Wang et al., 2009a).ier B.V. All rights reserved.
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Figure 1 Few promising compounds with quinoline ring system.
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2,4-Diphenyl-2-methyl-1,2 dihydroquinoline [8] has been
synthesized by using aniline and acetophenone in the presence
of a small pore size E4a zeolite catalyst (Hegedus et al., 2007).
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By stirring 2-amino substituted aromatic ketones and car-
bonyl compounds having a reactive a-methylene group in ethyl
ammonium nitrate (EAN) 2,3,4-trisubstituted quinolines [9]
have been developed (Zhou et al., 2008).
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Using 2-aminosubstituted ketone and ketone as reactants
poly-substituted quinolines [10] have been synthesized in aque-
ous media and solvent-free conditions in the presence of dode-
cylphosphonic acid (DPA) as catalyst (Ghassamipour and
Sardarian, 2009).
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OEtKouznetsov (2009) synthesized phenyl substituted quino-
lines [11] by subjecting a mixture of ethyl vinyl ether or ethyl
vinyl sulﬁde and N-arylaldimine to acidic catalysis in the pres-
ence of boron triﬂuoride etherate (BF3.OEt2) to yield 2,4-
substituted tetrahydroquinolines, which were then converted
to 2-phenyl substituted quinolines under vacuum distillation
with tosylic acid (p-TsOH).
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3,4-Dihydroquinolin-2-one [12] has been developed by
treating 2-iodoanilines and ethyl acrylate with Azobisisobuty-
ronitrile (AIBN) in presence of tributyltin hydride (n-Bu3SnH)
(Zhou et al., 2009).
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2-Phenyl-4-alkoxy quinoline [13] has been synthesized by
condensation and cyclization of 2-(2-trimethylsilyl)ethynyl)
aniline with arylaldehydes. The reaction is promoted by sulfu-
ric acid in the presence of methanol as solvent (Wang et al.,
2009b).
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Quinoline: A versatile heterocyclic 3Certain halogen-substituted quinolines [14] have been
synthesized by the condensation and cyclization of two mol-
ecules of o-haloacetophenones with urea or primary amines
(Qi et al., 2009).
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Iraj et al. (2010) synthesized 2,4-disubstituted quinolines
[15] through a one-pot reaction of structurally diverse 2-
aminoaryl ketones with various arylacetylenes in the pres-
ence of potassium dodecatugstocobaltate trihydrate
(K5CoW12O40Æ3H2O) as a reusable and environmentally be-
nign catalyst under microwave irradiation and solvent-free
conditions.
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Ultrasound promoted synthesis of quinolines [16] using basic
ionic liquids (BIL) in aqueousmedia has been reported byKow-
sari andMallakmohammadi (2011). The advantage of such pro-
cedure being that it is simple in operation and high yields are
obtained. The reaction involves treating isatin with aromatic
methyl ketones at ultrasonic frequencies of 20–50 kHz.
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One-step methodology has been introduced for the synthe-
sis of quinoline alkaloid analogues [17] (Zografos et al., 1999).
The reaction is based on a modiﬁcation of the Mukaiyama
aldol condensation, making use of the high reactivity of
lactones or anhydrides.
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Diversiﬁed 2-alkoxy- and 2-aroxy-3-substituted quinolines
[18] have been synthesized from o-alkynylaryl isocyanides
and alcohols and phenols promoted by 1,4-diazabicy-
clo[2.2.2]octane (DABCO) (Zhao et al., 2010).
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182,4-Disubstituted quinolines [19] have been synthesized
according to Meyer-Schuster rearrangement (Sarmaand Praja-
pati, 2008). In this method 2-aminoaryl ketones and phenyl-
acetylenes rearrange in the presence of a catalytic amount of
zinc triﬂuoromethanesulfonate in the ionic liquid 1-hexyl-3-
methylilmidazolium hexaﬂuorophosphate [hmim][PF6] result-
ing in 2,4-disubstituted quinolines. The same product has also
been obtained in the presence of indium(III)triﬂuoromethane-
sulfonate (In(CF3SO3)3) under microwave irradiation without
any solvent (Lekhok et al., 2008).O
R'
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Palladium-catalysed Wacker-type oxidative cyclization has
been proposed for the synthesis of 2-methylquinolines [20] with
good yields under mild conditions (Wang et al., 2011).R"
NH2
R'
OH
R
Pd(OAc)2
1,10-Phenanthroline
air
MeOH, 25o or 40oC, 36hr N CH3
R'
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Poly-substituted quinolines [21] have been developed by the
reaction of 2-aminobenzylic alcohol derivatives with ketones
or alcohols in the presence of base and benzophenone as hy-
dride scavenger (Martinez et al., 2008).KOtBu
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2,4-Disubstituted quinolines [22] have been synthesized by
cyclization of 2-iodoanilines with alkynyl aryl ketones in the
presence of nickel catalyst (Chen et al., 2006).R
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Horn et al. (2008) reported synthesis of quinolines [23] from
a,b-unsaturated ketones and o-aminophenylboronic acid
derivatives which is a modiﬁcation of the traditional Skraup-
Doebner-von Miller synthesis. The method has an advantage
that it can proceed under basic conditions rather than strongly
acidic conditions.
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4 A. Marella et al.The reaction of benzimidoyl chlorides with 1-(1-(allyl-
oxy)prop-2-ynyl)benzene (1,6-enynes) forms quinoline deriva-
tives [24] via palladium-catalysed Sonogashira coupling and
subsequent cyclization (Gao et al., 2010).
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Intramolecular cyclization of 1-azido-2-(2-propynyl)ben-
zene in the presence of electrophilic reagents in nitrometh-N N
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n = 2,4,6,8ane (CH3NO2) at room temperature or in the presence of
catalytic amounts of AuCl3/AgNTf2 in THF at 100 C gives
corresponding quinolines [25] in good yields (Huo et al.,
2010).
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3. Biological activity
3.1. Antimalarial
Most important use of the quinoline ring is its antimalarial
potential. Bisquinolines [26, 27] developed by Raynes et al.
(1996) are found to possess a good degree of antimalarial
activity against both chloroquine-resistant and chloroquine-
sensitive parasites. Analogues of ferrochloroquine [28] were
also found to have antimalarial activity by Chibale et al.
(2000). In these analogues carbon chain of chloroquine is re-
placed by hydrophobic ferrocenyl group. Certain 7-chloro-
quinolinyl thioureas [29, 30] synthesized by Mahajan et al.
(2007) are potential antimalarial agents. Modapa et al.
(2009) synthesized few ureido-4-quinolinamides [31] which
showed antimalarial effect at MIC of 0.25 mg/mL against
chloroquine-sensitive Plasmodium falciparum strain. Chloro-
quinolyl derivative [32] developed by Kovi et al. (2009) alsohas a potent antimalarial activity at submicromolar levels.
Certain 4-aminoquinoline triazines [33] synthesized by Kumar
et al. (2008) also have antimalarial activity screened against
chloroquinine (CQ) sensitive strain 3D7 of P. falciparum in
an in vitro model. Shiraki et al. (2011) developed certain 5-
aryl-8-aminoquinolines [34] with promising antimalarial
activity which had lesser haemolytic activity compared to taf-
enoquine. Acharya et al. (2008) synthesized and evaluated the
antimalarial activity of some pyridine–quinoline hybrids [35–
37] against chloroquine susceptible strain of P. falciparum.
Singh et al. (2011) developed antimalarial agents with 4-ani-
linoquinoline ring [38]. The compounds showed good activity
against chloroquine-sensitive P. falciparum strains as well as
against rodent malaria parasite P. yoeii.NCl
N
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3.2. Analgesic activity
4-Substituted-7-triﬂuoromethylquinolines [39, 40] synthesized
by Abadi et al. (2005) have been found to have a good analge-
sic activity. The activity is attributed to their nitric oxide
releasing properties. Gomtsyan et al. (2005) developed a quin-
oline [41] based analgesic agent whose activity was attributed
to its antagonism at Vanilloid receptors. A few quinoline deriv-
atives [42] developed by Manera et al. (2007) by acting as selec-
tive agonists at Cannabinoid CB2 receptors show their
analgesic activity.
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3.3. Anti-inﬂammatory activity
2-(Furan-2-yl)-4-phenoxy-quinoline [43, 44] derivatives devel-
oped by Chen et al. (2006) are found to be inhibitors of lyso-
zyme and b-glucuronidase release. Baba et al. (1996) developed
a quinoline derivative [45] with potent anti-inﬂammatory effect
in adjuvant arthritis rat model. Certain quinoline derivatives
[46, 47] have been developed for treating osteoarthritis by Gil-
bert et al. (2008). These are amino-acetamide inhibitors of
Aggrecanase-2.
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3.4. Antineoplastic
Some of the amido-anilinoquinolines [48] developed by Scott
et al. (2009) act as anti-tumour agents by inhibiting CSF-1R
kinase. Novel 4-hydroxyquinolines [49] synthesized by Mai et
al. (2009) are histone acetyltransferase (HAT) inhibitors.
Miller et al. (2009) developed a few 3-cyanoquinolines [50] as
6 A. Marella et al.inhibitors of insulin like growth factor receptors (IGF-1R) for
the treatment of cancer.
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A few 4-anilinoquinolines [51] developed by Assefa et al.
(2003) have been found to be tyrosine kinase inhibitors. Potent
quinoline carboxylic acids [52] have been developed by Chen
et al. (2009) which act by inhibiting insulin like growth factors.
Linomide [53] has been found to have action against androgen
responsive cancer and rat prostatic cancer by Vukanovic et al.
(1993). c-Met kinase inhibitory quinolines [54] with IC50 less
than 1 nM have been developed by Wang et al. (2011). It pro-
duces the inhibition of c-Met phosphorylation in c-Met depen-
dent cell lines.
Marganakop et al. (2012) developed certain 6,7,8-substi-
tuted thiosemicarbazones of 2-chloro-3-formyl-quinoline
derivatives [55] which had anticancer activities. The com-
pounds had a better drug score and c logP values.
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3.5. Antibacterial
Ma et al. (2009) synthesized phenoxy, phenylthio and benzyl-
oxy substituted quinolones [56] with a fair amount of anti-bac-
terial activity. Sanchez et al. (1988) developed certain 8-
substituted quinoline carboxylic acids [57] with anti-bacterial
activity. Upadhayaya et al. (2009) developed quinoline deriva-
tives [58] through molecular modelling techniques which were
found to be active against Mycobacterium tuberculosis H37Rv
strain. These were derivatives of 3-benzyl-6-bromo-2-methoxy
quinolines. De Souza et al. (2009) developed 7-chloro quino-
line derivatives [59] effective against multi-drug resistant tuber-
culosis. Lilienkampf et al. (2009) developed quinoline based
compound bearing an isoxazole containing side chain [60] ac-
tive against Mycobacterium tuberculosis. Some novel anti-
tubercular quinolines [61] have been developed by Eswaran
et al. (2010) using meﬂoquine as the lead, wherein active phar-
macophores viz. hydrazones, ureas, thioureas and pyrazoles
have been attached at the 4th position.
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Gholap et al. (2007) developed certain tetrahydroquinolines
[62] which are found to have a good degree of activity against
fungi Candida albicans, Fusarium oxysporum and Mucor sp.
Kharkar et al. (2009) developed a series of quinoline deriva-
tives [63] using terbenaﬁne as lead as antifungal agents. The
developed compounds contained different bulky aromatic
rings in the side chain. The compounds were designed using
LeapFrog drug design program. Kumar et al. (2011) developed
certain secondary amines [64] containing 2-chloroquinoline
and evaluated them for their antimycotic activity against
Aspergillus niger, A. ﬂavus, Monascus purpureus and Penicil-
lium citrinum. These are non-azole antimycotic agents.
N
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R = 4-Cl, 4-F, 3-NO2, 4-CH3, 
       2-Cl, 3,4,5-(OCH3)3
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N R
CH3
63 N Cl
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X = F, Cl, Br, CH3, NO2, Dichloro
Y = H, CH3 64
3.7. AntiviralAnilidoquinoline [65] derivatives synthesized by Ghosh et al.
(2008) are found to have a good degree of in vitro activity
against Japanese encephalitis virus. Certain quinoline deriva-
tives [66] synthesized by Chen et al. (2009) act by behaving
as HIV-1 Tat–TAR interaction inhibitors. Massari et al.
(2009) developed certain desﬂuoroquinolines [67] for the treat-
ment of HIV infection. Certain mono and polysubstituted
quinolines [68–70] synthesized by Fakhfakh et al. (2003) have
activity against HIV-1.
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3.8. Anthelmintic
Rossiter et al. (2005) synthesized substituted 2,4-arylquinolines
[71–74] which have a good degree of activity against the nem-
atode Haemonchus contortus. These arylquinolines maintain
their activity against levamisole, ivermectin and thiabendazole
resistant strains of H. contortus.
N
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OMe
71
N
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OMe
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72
73 74
N
OMe
OMe N
OMe
OMe
MeO
3.9. Anti-protozoal
Fournet et al. (1993) found that 2-substituted quinoline alka-
loids isolated from G. longiﬂora plant used for the treatment
of new world cutaneous leishmaniasis have in vitro antileishma-
nial activity against the extracellular forms of Leishmania spp.
These include 2-substituted 3-carbon chain quinoline alkaloids
and 2-substituted aryl quinoline alkaloids [75, 76]. Alkenyl and
alkynyl quinolines [77, 78] developed by Fakhfakh et al. (2003)
show activity against the causal agents of cutaneous leish-
maniasis, visceral leishmaniasis, African trypanosomiasis and
Chagas’ disease. Ma et al. (2009) developed certain quinolones
[79] which had activity against Trypanosoma cruzi. Franck et al.
(2004) developed quinoline derivatives [80, 81] which showed
activity against T. cruzi.
N
75
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N SiCH3
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3.10. Cardiovascular activity
Certain biarylether amide quinolines [82] developed by Berno-
tas et al. (2009) act as liver X receptor agonists and are useful
in conditions of dyslipidaemia. These agents also reverse the
conditions of arteriosclerosis. A few phenyl acetic acid based
quinolines [83] developed by Hu et al. (2007) also act as ago-
nists at liver X receptors. These agents have good binding
afﬁnity for LXRb and LXRa receptors. 4-Thiophenyl quino-
lines [84] developed by Cai et al. (2007) are HMG-CoA reduc-
tase inhibitors and have utility as hypocholesterolaemic agents.
Quinoline-4-carboxylic acids [85] synthesized by Lloyd et al.
(1994) are angiotensin II receptor antagonists and hence act
as hypotensive agents. Hypotensive activity of centhaquin
[86] has been demonstrated by Srimal et al. (1990) and it has
been shown to reduce the blood pressure in cat in a dose
dependent manner. Tetrahydroquinolines [87] which inhibit
cholesteryl ester transfer protein have been developed by Rano
et al. (2009). Tetrahydroquinolinamines [88, 89] developed by
Ramos et al. (2008) have been found to be inhibitors of platelet
aggregation.
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R2 = H, F, Cl or Substituted thiophenyl group;
R3 = H, F or Substituted thiophenyl group
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3.11. CNS effects
Quinoline based NK3 receptor antagonists [90, 91] with CNS
activity have been developed by Smith et al. (2009).
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3.12. Hypoglycaemic activity
Quinoline carboxyguanides [92] prepared by Edmont et al.
(2000) are hypoglycaemic agents.
N
MeO
Et
O
N
H
NH
N
H
O
NHR
. HCl
92
R = H, C(NH)NH2
3.13. Reproductive System
Certain tetrahydroquinolines [93] developed by Wallace et al.
(2003) are selective oestrogen receptor modulators.
Quinoline: A versatile heterocyclic 9N
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Bi et al. (2004) developed certain quinolines [94] which act
as potent PDE5 inhibitors thus having utility in the treatment
of erectile dysfunction.
N
H
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R4
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R1 = COOEt; R2 = H, CN; R3 = H, CF3; R4 = H, Et
3.14. Miscellaneous
Quinolines have been found to possess a number of other
activities as well.
Evans et al. (1991) developed certain quinoline based leuko-
triene synthesis inhibitors [95].
N O
OH
O
OH
95
Selective PDE4 inhibitor quinolines [96, 97] have been
developed by Lunniss et al. (2009) with utility in chronic
obstructive pulmonary disorder.
N
NH2
O
CH3
NH
F
S
O
O
CH3
OMe
N
NH2
O
CH3
NH
S
O
O
CH3
CN
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Quinoline 3-carboxamide [98] is used for the treatment of
chronic relapsing autoimmune encephalitis. This activity was
studied by Karussis et al. (1993).
N
NH2
O
98Bachiller et al. (2010a,b) have developed some novel ta-
crine–8-hydroxyquinoline hybrids [99] with activity against
Alzheimer’s. Tacrine has cholinesterase inhibition action while
8-hydroxyquinoline derivatives have metal-chelating, neuro-
protective and anti-oxidant properties.
Tacrine
N
H
N
H
N
OH
z R1
R2
99
Z = Alkyl chain; 
Str-I: R1 = R2 = H
Str-II: R1 = CH3; R2 = H
Str-III: R1 = H; R2 = Cl
Tetrahydroquinolin-6-yloxy propanes [100] have been
developed by Shakya et al. (2009) which are b-3 agonists.
N
H O
OH
N
SO2Ar
MeO
MeO
100
Certain aminoalkoxyquinolines [101] as somatostatin
receptor subtype-2 agonists have been reported by Wolkenberg
et al. (2011) which have utility in proliferative diabetic retinop-
athy and exudative age related macular degeneration.
N
O
NH
R
Cl
CH3
CH3
101
R = Aromatic ring
The 1,2,3,4-tetrahydroquinoline-2,2,4-trione oximes devel-
oped by Cai et al. (1996) [102] act as antagonists of NDMA
in glycine receptors. These compounds can be used as agents
against neurodegenerative diseases (e.g., Alzheimer’s disease).
N
H
O
O
NOH
R5
R6
R7
R8
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R = H,Cl,CH3,F
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